Product Center
Influenza virus subunit vaccine application accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-07
- Views:
(Summary description) On June 7, 2024, Ab&B Bio-Tech CO.,LTD.JS(hereinafter referred to as “Ab&B Bio”) declared that the application for “Influenza Virus Subunit Vaccine” was accepted by the Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (CDE).
Influenza virus subunit vaccine application accepted!
(Summary description) On June 7, 2024, Ab&B Bio-Tech CO.,LTD.JS(hereinafter referred to as “Ab&B Bio”) declared that the application for “Influenza Virus Subunit Vaccine” was accepted by the Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (CDE).
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-07 14:01
- Views:
On June 7, 2024, Ab&B Bio-Tech CO.,LTD.JS(hereinafter referred to as “Ab&B Bio”) declared that the application for “Influenza Virus Subunit Vaccine” was accepted by the Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (CDE).
Source: State Drug Administration Drug Evaluation Center Government Service Website
At present, influenza virus is still one of the important respiratory pathogens threatening human public health, seasonal influenza outbreaks or occasional cross-species transmission of influenza viruses and pandemics to human health and socio-economic impact of the WHO position paper on influenza vaccination and the Chinese Center for Disease Control and Prevention of the Chinese influenza vaccine prevention and vaccination technical guidelines clearly put forward, the annual influenza vaccine is the most cost-effective measures to prevent influenza, which can significantly reduce the incidence of influenza. The WHO position paper on influenza vaccination and the Chinese Center for Disease Control and Prevention (CDC) Technical Guidelines for Influenza Vaccination in China clearly state that annual influenza vaccination is the most cost-effective measure to prevent influenza, and it can significantly reduce the risk of influenza and serious complications.
This year, WHO suggested that after March 2020, the global influenza surveillance network had not detected the B/Yamagata virus, and therefore recommended that the influenza vaccine should no longer include the B/Yamagata lineage component. CWB responded positively and acted quickly to complete the declaration of the influenza virus subunit vaccine and realize the product launch as soon as possible, so as to scientifically respond to the prevention and control of influenza and provide a variety of influenza vaccine choices for the society.
CWB has always insisted on not making simple copies, and has plowed into the field of subunit influenza technology. Up to now, the subunit influenza vaccine family of Ab&B Biotechnology includes: quadrivalent influenza virus subunit vaccine for people aged 6-35 months, quadrivalent influenza virus subunit vaccine for people aged 3 years and above, quadrivalent influenza virus subunit vaccine (adjuvant) for the elderly, trivalent influenza virus subunit vaccine, trivalent influenza virus subunit vaccine (adjuvant) for the elderly, as well as general subunit influenza vaccines under development, precisely covering the needs of various groups of people. These vaccines precisely cover the needs of various groups of people. Among them, the quadrivalent influenza virus subunit vaccine (HRK-X®) for people aged 3 years and above has been marketed and sold, and has been well received by vaccine recipients for its high purity, low side effects of inoculation, good safety, and comprehensive protection. Ab&B Bio will also adhere to the principles of innovation-driven, quality-leading, and realize the marketing and sales of all varieties of influenza vaccine products as soon as possible, contributing more to the prevention and control of influenza with Ab&B power!
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
